0.0450
0.0000
(0.00%)
At close: April 11 at 4:00:00 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Stanislaw R. Burzynski M.D., Ph.D. | Chairman, CEO & President | -- | -- | 1943 |
| Mr. Patryk P. Goscianski M.B.A. | CFO, Treasurer & Secretary | -- | -- | 1978 |
| Dr. Tomasz Janicki M.D. | Vice President of Clinical Trials | -- | -- | 1966 |
Burzynski Research Institute, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was incorporated in 1984 and is headquartered in Houston, Texas.
Corporate Governance
Burzynski Research Institute, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 27, 2025 at 8:00 PM UTC - June 2, 2025 at 8:00 PM UTC
Burzynski Research Institute, Inc. Earnings Date